D-mannose suppresses oxidative response and blocks phagocytosis in experimental neuroinflammation

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 118; no. 44; pp. 1 - 8
• Main Authors: Wang, Jing, Motlagh, Negin Jalali, Wang, Cuihua, Wojtkiewicz, Gregory R., Schmidt, Stephan, Chau, Cindy, Narsimhan, Radha, Kullenberg, Enrico G., Zhu, Cindy, Linnoila, Jenny, Yao, Zhenwei, Chen, John W.
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 02.11.2021
• Subjects: Animals; Biological Sciences; Cell activation; Central nervous system; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental - drug therapy; Experimental allergic encephalomyelitis; Female; Gadolinium; Inflammation; Iron oxides; Macrophages; Magnetic resonance imaging; Mannose; Mannose - pharmacology; Mannose - therapeutic use; Mice; Mice, Inbred C57BL; Microglia; Molecular Imaging; Monosaccharides; Multiagent systems; Multiple sclerosis; Myelin; Nanoparticles; Neurological diseases; Oxidative stress; Oxidative Stress - drug effects; Peroxidase; Phagocytosis; Phagocytosis - drug effects; Signs and symptoms; phagocytosis; d-mannose; neuroinflammation; imaging; oxidative stress
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.2107663118

Inflammation drives the pathology of many neurological diseases. D-mannose has been found to exert an antiinflammatory effect in peripheral diseases, but its effects on neuroinflammation and inflammatory cells in the central nervous system have not been studied. We aimed to determine the effects of D-mannose on key macrophage/microglial functions—oxidative stress and phagocytosis. In murine experimental autoimmune encephalomyelitis (EAE), we found D-mannose improved EAE symptoms compared to phosphate-buffered saline (PBS)-control mice, while other monosaccharides did not. Multiagent molecular MRI performed to assess oxidative stress (targeting myeloperoxidase [MPO] using MPO-bis-5-hydroxytryptamide diethylenetriaminepentaacetate gadolinium [Gd]) and phagocytosis (using cross-linked iron oxide [CLIO] nanoparticles) in vivo revealed that D-mannose–treated mice had smaller total MPO-Gd⁺ areas than those of PBS-control mice, consistent with decreased MPO-mediated oxidative stress. Interestingly, D-mannose–treated mice exhibited markedly smaller CLIO⁺ areas and much less T2 shortening effect in the CLIO⁺ lesions compared to PBS-control mice, revealing that D-mannose partially blocked phagocytosis. In vitro experiments with different monosaccharides further confirmed that only D-mannose treatment blocked macrophage phagocytosis in a dose-dependent manner. As phagocytosis of myelin debris has been known to increase inflammation, decreasing phagocytosis could result in decreased activation of proinflammatory macrophages. Indeed, compared to PBS-control EAE mice, D-mannose–treated EAE mice exhibited significantly fewer infiltrating macrophages/activated microglia, among which proinflammatory macrophages/microglia were greatly reduced while antiinflammatory macrophages/microglia increased. By uncovering that D-mannose diminishes the proinflammatory response and boosts the antiinflammatory response, our findings suggest that D-mannose, an over-the-counter supplement with a high safety profile, may be a low-cost treatment option for neuroinflammatory diseases such as multiple sclerosis.